KD 027

Drug Profile

KD 027

Alternative Names: KD027; SLX 2101; SLx-2101

Latest Information Update: 20 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Surface Logix
  • Developer Kadmon Pharmaceuticals; Surface Logix
  • Class Cardiovascular therapies; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Erectile dysfunction; Hypertension; Raynaud's disease

Most Recent Events

  • 14 Apr 2014 KD 027 is still in phase II trials for Hypertension
  • 14 Apr 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
  • 14 Apr 2014 Discontinued - Phase-II for Raynaud's disease in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top